A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Start Date
6/3/2026
Completion Date
12/1/2027
Summary
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Detailed Description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
Eligibility Criteria
Age Range: 18 years to 70 years
Interventions
D-2570 Tablet
Placebo Tablets
Conditions
Locations
Study Center
Birmingham, Alabama 35244
United States
Study Center
Phoenix, Arizona 85008
United States
Study Center
Chula Vista, California 91910
United States
Study Center
Fountain Valley, California 92708
United States
Study Center
Fremont, California 94538
United States
Study Center
Los Angeles, California 90017
United States
Study Center
Los Angeles, California 90024
United States
Study Center
San Diego, California 92123
United States
Study Center
Fort Lauderdale, Florida 33308
United States
Study Center
Miramar, Florida 33027
United States
Study Center
Ocala, Florida 34470
United States
Study Center
Tampa, Florida 33607
United States
Study Center
Sandy Springs, Georgia 30328
United States
Study Center
Savannah, Georgia 31419
United States
Study Center
Idaho Falls, Idaho 83404
United States
Study Center
Clarksville, Indiana 40241
United States
Study Center
Louisville, Kentucky 40241
United States
Study Center
Mayfield Heights, Ohio 44124
United States
Study Center
Philadelphia, Pennsylvania 19103
United States
Study Center
San Antonio, Texas 78218
United States